GEM exposure to cancer cells increases the amount of cytoplasmic HuR and promotes its association with dCK mRNA, which encodes the enzyme that activates GEM, establishing a positive feedback loop that improves its therapeutic efficacy. The gene discussed is ELAVL1; the disease is cancer.